GRI Bio Secures New U.S. Patent For Novel Immunomodulatory Compound Compositions Targeting Inflammatory, Fibrotic, And Autoimmune Diseases

GRI Bio, Inc., a biotechnology company developing a pipeline of immune cell modulators for inflammatory, fibrotic, and autoimmune diseases, announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,528,775. This new patent provides strong intellectual property protection for several novel compound compositions that are central to the company’s platform of immunomodulatory technologies.

The patent covers composition-of-matter claims for a unique group of proprietary compounds defined by linked molecular structures that create pyrrolidine, piperidine, or azepane ring systems. These specific structural features mark an important scientific advancement for the company. They also represent a separate class of compounds not included in GRI Bio’s previously issued patents, further reinforcing the strength and durability of the company’s overall intellectual property portfolio.

Marc Hertz, Chief Executive Officer of GRI Bio, stated that the patent is a reflection of the company’s thoughtful intellectual property strategy and deep scientific capabilities. He noted that this newly granted protection secures an independent and highly valuable portion of the company’s expanding chemistry platform.

The issuance of this patent supports GRI Bio’s broader work focused on modulating Natural Killer T (NKT) cell biology, an important area of research linked to multiple immune-driven conditions. It also aligns with the company’s ongoing efforts to develop targeted therapies for inflammatory, fibrotic, and autoimmune diseases.

GRI Bio continues to advance its lead candidate, GRI-0621, while also leveraging its expanding chemistry platform and a library of more than 500 proprietary compounds. This growing scientific foundation is expected to support future pipeline growth and may create opportunities for strategic collaborations.